Skip to Main Content

Print | Bookmark | Email | Font Size: + |

May 23, 2024

July 2024 HCPCS Updates – New, Revised, and Discontinued HCPCS Codes and Modifiers – Revised

The following information is based on the July 2024 Healthcare Common Procedure Coding System (HCPCS) file. There are several updates that will be effective July 1, 2024. Please keep in mind that the appearance of a HCPCS code is not an indication of coverage by the DME MAC.

This following list contains added HCPCS codes that will be effective July 1, 2024.

HCPCS DESCRIPTION
J0211 Injection, sodium nitrite 3 mg and sodium thiosulfate 125 mg (nithiodote)
J0687 Injection, cefazolin sodium (wg critical care), not therapeutically equivalent to j0690, 500 mg
J0872 Injection, daptomycin (xellia), unrefrigerated, not therapeutically equivalent to j0878 or j0873, 1 mg
J1597 Injection, glycopyrrolate (glyrx-pf), 0.1 mg
J1598 Injection, glycopyrrolate (fresenius kabi), not therapeutically equivalent to j1596, 0.1 mg
J1748 Injection, infliximab-dyyb (zymfentra), 10 mg
J2183 Injection, meropenem (wg critical care), not therapeutically equivalent to j2185, 100 mg
J2246 Injection, micafungin in sodium (baxter), not therapeutically equivalent to j2248, 1 mg
J2267 Injection, mirikizumab-mrkz, 1 mg
J2373 Injection, phenylephrine hydrochloride (immphentiv), 20 micrograms
J2468 Injection, palonosetron hydrochloride (avyxa), not therapeutically equivalent to j2469, 25 micrograms
J2470 Injection, pantoprazole sodium, 40 mg
J2471 Injection, pantoprazole (hikma), not therapeutically equivalent to j2470, 40 mg
J3247 Injection, secukinumab, intravenous, 1 mg
J3263 Injection, toripalimab-tpzi, 1 mg
J3393 Injection, betibeglogene autotemcel, per treatment
J3394 Injection, lovotibeglogene autotemcel, per treatment
J7171 Injection, adamts13, recombinant-krhn, 10 iu
J8611 Methotrexate (jylamvo), oral, 2.5 mg
J8612 Methotrexate (xatmep), oral, 2.5 mg
J9361 Injection, efbemalenograstim alfa-vuxw, 0.5 mg
Q5137 Injection, ustekinumab-auub (wezlana), biosimilar, subcutaneous, 1 mg
Q5138 Injection, ustekinumab-auub (wezlana), biosimilar, intravenous, 1 mg

The following HCPCS codes have description/verbiage changes that will be effective July 1, 2024.

HCPCS DESCRIPTION
J0134 Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg
J0136 Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg
J0137 Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg
J0173 Injection, epinephrine (belcher), not therapeutically equivalent to j0171, 0.1 mg
J0401 Injection, aripiprazole (abilify maintena), 1 mg
J0651 Injection, levothyroxine sodium (fresenius kabi), not therapeutically equivalent to j0650, 10 mcg
J0652 Injection, levothyroxine sodium (hikma), not therapeutically equivalent to j0650, 10 mcg
J0873 Injection, daptomycin (xellia), not therapeutically equivalent to j0878 or j0872, 1 mg
J0893 Injection, decitabine (sun pharma), not therapeutically equivalent to j0894, 1 mg
J1574 Injection, ganciclovir sodium (exela), not therapeutically equivalent to j1570, 500 mg
J1806 Injection, esmolol hydrochloride (wg critical care), not therapeutically equivalent to j1805, 10 mg
J1921 Injection, labetalol hydrochloride (hikma), not therapeutically equivalent to j1920, 5 mg
J2021 Injection, linezolid (hospira), not therapeutically equivalent to j2020, 200 mg
J2184 Injection, meropenem (b. braun), not therapeutically equivalent to j2185, 100 mg
J2251 Injection, midazolam hydrochloride (wg critical care), not therapeutically equivalent to j2250, per 1 mg
J2272 Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg
J2281 Injection, moxifloxacin (fresenius kabi), not therapeutically equivalent to j2280, 100 mg
J2599 Injection, vasopressin (american regent), not therapeutically equivalent to j2598, 1 unit
J2806 Injection, sincalide (maia), not therapeutically equivalent to j2805, 5 micrograms
J3244 Injection, tigecycline (accord), not therapeutically equivalent to j3243, 1 mg
J3371 Injection, vancomycin hcl (mylan), not therapeutically equivalent to j3370, 500 mg
J3372 Injection, vancomycin hcl (xellia), not therapeutically equivalent to j3370, 500 mg
J9046 Injection, bortezomib (dr. reddy's), not therapeutically equivalent to j9041, 0.1 mg
J9172 Injection, docetaxel (ingenus), not therapeutically equivalent to j9171, 1 mg
J9258 Injection, paclitaxel protein-bound particles (teva), not therapeutically equivalent to j9264, 1 mg
J9259 Injection, paclitaxel protein-bound particles (american regent), not therapeutically equivalent to j9264, 1 mg
J9294 Injection, pemetrexed (hospira), not therapeutically equivalent to j9305, 10 mg
J9296 Injection, pemetrexed (accord), not therapeutically equivalent to j9305, 10 mg
J9314 Injection, pemetrexed (teva), not therapeutically equivalent to j9305, 10 mg
J9322 Injection, pemetrexed (blue point), not therapeutically equivalent to j9305, 10 mg
J9393 Injection, fulvestrant (teva), not therapeutically equivalent to j9395, 25 mg
Q2055 Idecabtagene vicleucel, up to 510 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose

The following listing contains discontinued HCPCS codes, along with the cross-walked HCPCS codes (if applicable). Please note, not all discontinued HCPCS codes will have a cross-walked HCPCS code.

HCPCS DISCONTINUE DATE CROSSWALK HCPCS CODE
J2780 06/30/2024  
J9371 06/30/2024  

Publication History:

May 23, 2024 Originally published
June 27, 2024 Added J7171 - Injection, adamts13, recombinant-krhn, 10 iu

spacer

26 Century Blvd Ste ST610, Nashville, TN 37214-3685 © CGS Administrators, LLC. All Rights Reserved